, Driving Performance on land and on water: Stronger and lighter: the eleventh boat from Mercedes-AMG and Cigarette Racing sets new benchmarks through extensive use of carbon-fibre
, Driving Performance on land and on water: Stronger and lighter: the eleventh boat from Mercedes-AMG and Cigarette Racing sets new benchmarks through extensive use of carbon-fibre

Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint® BluePrint® Breast Cancer Kit to Market

RIJSWIJK, NETHERLANDS and IRVINE, CA, AMSTERDAM, – 19 December 2017 – Bluebee, a company driving global genomic data-driven medicine, and  Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, have partnered to provide a secure, convenient, data processing solution for Agendia’s MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, which is intended for prognostic use in a clinical setting.

Initially available in Europe, the next-generation sequencing (NGS)-based MammaPrint BluePrint Kit will enable cancer centers to run the test in-house. The partnership with Bluebee enables secure global access to test results, while ensuring all data complies with local data privacy and residency regulations, an essential development in the preparation for the European launch in early 2018.

The MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a binary Low or High Risk-of-cancer recurrence result, while the BluePrint test analyses 80 genes to classify breast cancer into four functional molecular subtypes. Together, the Kit will help physicians personalize treatment management by identifying women who are at a genomic Low Risk for disease recurrence and unlikely to benefit from chemotherapy.

Hans Cobben, Chief Executive Officer of Bluebee said:

“Through this partnership, Bluebee enables Agendia to make the data tangible and actionable. We are generating real clinical solutions out of science, improving human healthcare and enabling a truly individualized approach, this will take the fight against breast cancer to a new level.”

Dr. Marjolaine Baldo, Commercial Vice President, EMEA at Agendia said:

“The launch of the NGS-based MammaPrint BluePrint Kit will bring our breast cancer tests to cancer centers across Europe, ensuring that even more patients and their physicians can benefit from the test. Therefore, when choosing a data processing partner, it was important for us to work with a team that could deliver these results in a highly secure form. We are very pleased to partner with Bluebee as we finalize the development of the MammaPrint BluePrint Kit ahead of European launch.”

Comments are closed.